Why the study?
Does perioperative supplementation with omega-3 fatty acids alter leukotriene production and reduce postoperative complications in patients undergoing elective colorectal cancer surgery?
Does perioperative supplementation with omega-3 fatty acids alter leukotriene production and reduce postoperative complications in patients undergoing elective colorectal cancer surgery?
Answers are grounded in this paper and cite their sources.
Perioperative omega-3 fatty acid supplementation alters inflammatory leukotriene profiles but does not reduce postoperative complications in colorectal cancer surgery patients.
Omega-3 fatty acids (n-3 FA) may have beneficial clinical and immune-modulating effects in surgical patients. In a randomized, double-blind, prospective, placebo-controlled trial, 148 patients referred for elective colorectal cancer surgery received an n-3 FA-enriched oral nutritional supplement (ONS) providing 2.0 g of eicosapentaenoic acid (EPA) and 1.0 g of docosahexaenoic acid (DHA) per day or a standard ONS for seven days before surgery. On the day of operation, there was a significant increase in the production of leukotriene B5 (LTB5) (p < 0.01) and 5-hydroxyeicosapentaenoic acid (5-HEPE) (p < 0.01), a significant decrease in the production of leukotriene B4 (LTB4) (p < 0.01) and a trend for a decrease in the production of 5-hydroxyeicosatetraenoic acid (5-HETE) (p < 0.1) from stimulated neutrophils in the active group compared with controls. There was no association between LTB4 values and postoperative complications. In conclusion, oral n-3 FA exerts anti-inflammatory effects in surgical patients, without reducing the risk of postoperative complications.
No takes yet. Share an insight, caveat, or question.
Sørensen et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: